Mitochondrial peptides compared: medicine versus early biology
How FDA-approved elamipretide differs from preclinical MOTS-c and Humanin research in status, evidence, muscle claims, and healthy-aging hype.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
The quick overview
Elamipretide, MOTS-c, and Humanin all appear in discussions of mitochondria, energy, muscle function, and aging, but they occupy completely different evidence categories.
Forzinity, an elamipretide product, has accelerated FDA approval for a narrow Barth syndrome indication. MOTS-c and Humanin remain largely preclinical research subjects with no FDA-approved drug product and no established human wellness or longevity benefit.
Side-by-side comparison
| Peptide | Status | Evidence | Studied for |
|---|---|---|---|
| Elamipretide | FDA approved for specific uses | Moderate human evidence | Barth syndrome; Primary mitochondrial myopathy; Mitochondrial function and muscle energetics |
| MOTS-c | Preclinical research | Mostly animal or lab research | Insulin sensitivity and metabolic regulation in animal models; Exercise adaptation and physical capacity; Age-related metabolic decline |
| Humanin | Preclinical research | Mostly animal or lab research | Neuroprotection in laboratory and animal models; Cognitive aging associations; Metabolic and insulin-signaling biology |
Studied for
Barth syndrome · Primary mitochondrial myopathy · Mitochondrial function and muscle energetics
Studied for
Insulin sensitivity and metabolic regulation in animal models · Exercise adaptation and physical capacity · Age-related metabolic decline
Studied for
Neuroprotection in laboratory and animal models · Cognitive aging associations · Metabolic and insulin-signaling biology
Approved versus investigational
An FDA approval means the agency reviewed evidence for a specific product, population, and use. It does not validate other molecules in the same family or uses outside the label. “In Phase 3” still means investigational.
What researchers are studying
- Rare mitochondrial disease and muscle strength
- Metabolic and exercise signaling
- Cell survival and neuroprotection
- Age-related decline and healthy-aging mechanisms
Risks and reasons for caution
- An FDA approval based on a small rare-disease program cannot be generalized to healthy people or other mitochondrial conditions.
- Natural blood levels, genetic associations, cells, and animal models do not establish a benefit from taking a peptide product.
- FDA identifies major human-exposure and product-quality gaps for compounded MOTS-c.
What remains uncertain
- Whether Forzinity's intermediate endpoint will translate into confirmed patient benefit
- Whether administered MOTS-c or Humanin can improve any clinical human outcome
- Long-term safety and the relevance of preclinical aging findings to people
Questions to ask a healthcare professional
1. Is the claim tied to the exact peptide, formulation, and population studied?
2. Is the evidence a human outcome, a biomarker, or a cell or animal result?
3. Does the claimed benefit match the narrow approved use, if any?
4. What human safety data exist for the actual product?
Plain-English takeaway
Mitochondrial biology is a research frontier, not a shared clinical indication. Elamipretide has one narrow accelerated approval; MOTS-c and Humanin do not yet have direct evidence as human therapies.
References
- 1FDA prescribing information: Forzinity
Approval scope, intermediate endpoint, warnings, and evidence for elamipretide.
- 2FDA: selected compounded-peptide safety risks
FDA summary of human-exposure, immune, impurity, and product-characterization gaps for MOTS-c.
- 3MOTS-c metabolic research
Preclinical metabolic study that cannot establish human treatment benefit.
- 4Humanin cognitive-aging research
Cell, animal, and human association evidence—not a human treatment trial.